References
- Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11b-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 1994; 105: R11–R17
- Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266: 16653–16658
- Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999; 57: 249–324
- Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Houssman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237(4812)268–275
- Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, deKloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2(8618)986–989
- Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242(4878)583–585
- Morris DJ, Semafuko WE, Latif SA, Vogel B, Grimes CA, Sheff MF. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension 1992; 20(3)356–360
- Dale SL, Chattoraj SC, Biswas A, Gajewski A, Nuzzo P. Identification of 19–norprogesterone in pregnant rat urine. Steroids 1991; 56(9)472–476
- Bujalska I, Shimojo M, Howie A, Stewart PM. Human 11 beta-hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 1997; 77: 77–82
- Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994; 79(2)480–484
- Geller DS, Farhi A, Pinkerton N, Fradley M, Montz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119–123, 7July
- White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21(3)245–291
- Paris J, Botella J, Fournau P, Bonnet P, Thevenot R. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships. J Pharmacol Exp Ther 1987; 243(1)288–291
- Funder JW, Adam WR. 19-Nor progesterone is a mineralocorticoid agonist. Endocrinology 1981; 109(1)313–315
- Hall CE, Gomez-Sanchez CE, Hungerford S, Gomez-Sanchez EP. Mineralocorticoid and hypertensive effects of 19-nor-progesterone. Endocrinology 1981; 109(4)1168–1175
- Komanicky P, Melby JC. Experimental hypertension induced by 19-nor-progesterone treatment in the rat. Endocrinology 1981; 109(4)1164–1167
- Spence CD, Coghlan JP, Denton DA, Gomez-Sanchez CE, Mills EM, Nelson MA, Whitworth JA, Scoggins BA. The blood pressure and metabolic effects of 19-nor-deoxycorticosterone and 19-nor-progesterone in sheep. Clin Exp Hypertens A 1984; 6(9)1591–1600
- Schiff MJ, Schwartz JH, Bengele HH, Dale SL, Melby JC, Alexander EA. Mineralocorticoid activity of 19-nor-corticosterone and 19-nor-progesterone in the toad bladder. Endocrinology 1984; 115(4)1235–1238
- Wynne KN, Mercer J, Stockigt JR, Funder JW. 19-nor analogs of adrenal steroids: mineralocorticoid and glucocorticoid receptor activity. Endocrinology 1980; 107(5)1278–1280
- Griffing GT, Holbrook MM, Bencsath FA, Melby JC. Renal 21-hydroxylation of 19-hydroxy-progesterone to 19-hydroxy-deoxycorticosterone. J Steroid Biochem 1989; 33(5)895–898
- Melby JC, Dale SL, Holbrook M, Griffing GT. 19-Nor-corticosteroids in experimental and human hypertension. Clin Exp Hypertens A 1982; 4(9–10)1851–1867